In This Section

Program

Program in Progress
(as of JuLY 29, 2021)

Thursday, October 7

Poster Sessions
9 a.m. (on-demand throughout conference)
Educational Sessions
10 – 11:20 A.M.
EDUCATIONAL SESSION 1: Exploiting Synthetic Lethality
Cochairs: Eytan Ruppin, National Cancer Institute, Bethesda, Maryland, and Barbara Weber, Tango Therapeutics, Boston, Massachusetts

Introduction
Barbara Weber

Uncovering the principles that govern synthetic lethality in cancer
Christopher Lord, The Institute of Cancer Research, London, England

Synthetic lethality in microsatellite unstable cancers
André Nussenzweig, National Cancer Institute, Bethesda, Maryland

Panel Discussion

EDUCATIONAL SESSION 2: Novel Clinical Trial Designs and Development of Next-gen Investigators for Complex Anticancer Agents
Cochairs: Philippe L. Bedard, UHN Toronto General Hospital, Toronto, ON, Canada, and Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Introduction
Philippe L. Bedard

Early phase trials to establish proof of concept for adoptive cellular therapy for solid tumors
Prasad S. Adusumilli, Memorial Sloan Kettering Cancer Center, New York, New York

Response adaptive randomization to prioritize promising investigational agents: I-SPY2
Laura J. Esserman

Panel Discussion

Additional speaker to be announced

Break
11:20 – 11:35 a.m.
Welcome and Opening Keynote Address
11:35 a.m. – 12:35 p.m.

Welcome from Scientific Committee Cochairs
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
James L. Gulley, National Cancer Institute, Bethesda, Maryland
Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, England

Introduction of Keynote Speaker
Ruth Plummer

ctDNA and low dose CT for early-stage lung cancer screening: The SUMMIT Study
Samuel Janes, University College London, London, England

Discussion

Break
12:35 – 12:50 p.m.
PLenary Session 1: Tumor-targeted Conjugates: A Growing Family
Cochairs: Puja Sapra, AstraZeneca, Gaithersburg, Maryland, and Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland
12:50 – 2:40 p.m.

Introduction
Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland

Title to be announced
Puja Sapra, AstraZeneca, Gaithersburg, Maryland

Title to be announced
Meredith McKean, Sarah Cannon Research Institute, Nashville, Tennessee

Title to be announced
Timothy B. Lowinger, Mersana Therapeutics, Cambridge, Massachusetts

Panel Discussion

Break
2:40 – 2:55 p.m.
Concurrent Sessions 1-3
2:55 – 4:30 p.m.
CONCURRENT SESSION 1: Clinical Utility and Applications of New Computational Technologies
Cochairs: Benjamin Haibe-Kains, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada, and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, Texas

Title to be announced
Chris McIntosh, University of Toronto, Toronto, ON, Canada

Additional speakers to be announced

CONCURRENT SESSION 2: Drugs Targeting Metabolism
Cochairs: Stanley Lipkowitz, National Cancer Institute, Bethesda, Maryland, and Jean-Emmanuel Sarry, INSERM Cancer Research Center, Toulouse, France

Mitochondrial determinants of response and resistance to therapies in acute myeloid leukemia
Jean-Emmanuel Sarry

Panel Discussion

Additional speakers to be announced

CONCURRENT SESSION 3: Extracellular Vesicles as Therapeutic Targets
Cochairs: Toby T. Hecht, National Cancer Institute, Rockville, Maryland, and Jennifer C. Jones, National Cancer Institute, Bethesda, Maryland

Exosome-driven suppression of the anti-tumor immune response
Robert H. Blelloch, University of California, San Francisco, California

Title to be announced
Theresa L. Whiteside, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Panel Discussion

Break
4:30 – 4:45 p.m.
Keynote Address
4:45 – 5:35 p.m.

Introduction of Keynote Speaker
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

CRISPR and gene modification for cancer therapeutics
Jennifer A. Doudna, UC Berkeley, Berkeley, California

Discussion

Friday, October 8

Plenary Session 2: New Drugs on the Horizon
Cochairs: James L. Gulley, National Cancer Institute, Bethesda, Maryland, and Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
10 – 11:50 a.m.

Speakers to be selected from highly rated abstracts

Break
11:50 a.m. – 12:05 p.m.
PLENARY SESSION 3: Bispecific T cell Engagers and Next-gen CAR T Therapies: Pros and Cons of These Strategies
Cochairs: Kapil Dhingra, KAPital Consulting LLC, Sparta, New Jersey, and Jeffrey A. Moscow, National Cancer Institute, Bethesda, Maryland
12:05 – 1:55 p.m.

Introduction
Kapil Dhingra

Title to be announced
Patrick A. Baeuerle, MPM Capital, Cambridge, MA

Title to be announced
Hans J. van der Vliet, Amsterdam University Medical Center, Amsterdam, Netherlands      

Panel Discussion

Additional speaker to be announced

Break
1:55 – 2:10 p.m.
Concurrent Sessions 4-6
2:10 – 3:45 p.m.
CONCURRENT SESSION 4: Novel Precision Medicine Combination Trials
Cochairs: James H. Doroshow, National Cancer Institute, Bethesda, Maryland, and Elena Garralda, Vall D’Hebron Institute of Oncology, Barcelona, Spain

Introduction
Elena Garralda

Title to be announced
James H. Doroshow

Panel Discussion

Additional speaker to be announced

CONCURRENT SESSION 5: Preclinical Models and Predictive Value
Cochairs: Lori S. Friedman, ORIC Pharmaceuticals, South San Francisco, California, and Zoë Weaver Ohler, NCI-Frederick/Leidos Biomedical Research, Inc., Frederick, Maryland

Introduction
Zoë Weaver Ohler

Title to be announced
Lori S. Friedman

Panel Discussion

Additional speaker to be announced

CONCURRENT SESSION 6: Radiopharmaceuticals Coming of Age
Cochairs: Beverly A. Teicher, National Cancer Institute, Bethesda, Maryland, and Rebecca K.S. Wong, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

Introduction
Beverly A. Teicher

Title to be announced
Charles A. Kunos, University of Kentucky College of Medicine, Lexington, Kentucky

Title to be announced
David A. Jaffray, The University of Texas MD Anderson Cancer Center, Houston, Texas

Panel Discussion

AACR Chemistry in Cancer Research (CICR) Working Group Town Hall
4 – 5 p.m.

Saturday, October 9

PLENARY SESSION 4: DNA Damage Response Beyond PARP
Cochairs: Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, England, and Ioannis Gounaris, Merck-Serono Ltd., Feltham, England
10 – 11:50 a.m.

Introduction
Ioannis Gounaris

Title to be announced
Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA

Targeting the DDR beyond PARP inhibitors: Novel agents and rational combinations
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

Title to be announced
Ruth Plummer

Panel Discussion

Break
11:50 a.m. – 12:05 p.m.
PLENARY SESSION 5: Drugging Difficult Targets
Cochairs: Fiona H. Blackhall, University of Manchester, Manchester, England, and Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, Massachusetts
12:05 – 1:55 p.m.

Introduction
Fiona H. Blackhall

Mechanisms of acquired resistance to KRAS G12C inhibitors: Opportunities and challenges
Pasi A. Jänne

Development on inhibitors of KRAS G12D
James G. Christensen, Mirati Therapeutics, San Diego, California         

Discovery and development of RAS(ON) inhibitors beyond KRAS G12C
Stephen Kelsey, Revolution Medicines, Inc., Redwood City, California

Panel Discussion

Break
1:55 – 2:10 p.m.
Concurrent Sessions 7-9
2:10 – 3:45 p.m.
CONCURRENT SESSION 7: Targeting Molecular Residual Disease with ctDNA Technologies
Cochairs: Benjamin Besse, Institut Gustave Roussy, Villejuif, France, and Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Introduction
Benjamin Besse

Clinical application of ctDNA in the MRD setting
Jeanne Tie

Technical considerations in analyzing circulating DNA for the detection of the MRD and alternative methods based on cirDNA origin and topology
Alain Thierry, Institut de Recherche en Cancérologie de Montpellier, Montepellier, France

Panel Discussion

CONCURRENT SESSION 8: Tumor Microbiome
Cochairs: Tim F. Greten, National Cancer Institute, Bethesda, Maryland, and Laurence Zitvogel, Institute Gustave Roussy, Villejuif, France

Title to be announced
Jennifer A. Wargo                   

Title to be announced
Maria Rescigno, Humanitas University, Milan, Italy

Panel Discussion

CONCURRENT SESSION 9: Protein-Protein Inhibitors (PPI) in Hematologic Malignancies: Challenges and Promise
Cochairs: Zaneta Nikolovska-Coleska, University of Michigan, Ann Arbor, Michigan. Cochair to be announced

Sunday, October 10

PLENARY SESSION 6: HER2-directed Therapies – Dedicated to the Memory of José Baselga
Cochairs: Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, and Martine J. Piccart, Institut Jules Bordet, Brussels
10 – 11:50 a.m.

This session is dedicated to the memory of José Baselga.

Introduction
Carlos L. Arteaga and Martine J. Piccart

Title to be announced
Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Title to be announced
Aleix Prat, Hospital Clinic Barcelona, Barcelona, Spain

Title to be announced
Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA

Panel Discussion

Break
11:50 a.m. – 12:05 p.m.
PLENARY SESSION 7: Non T-cell Therapies
Cochairs: Rosandra N. Kaplan, National Cancer Institute, Bethesda, Maryland, and Frederick L. Locke, Moffitt Cancer Center, Tampa, Florida
12:05 – 1:55 p.m.
Break
1:55 – 2:10 p.m.
PLENARY SESSION 8: Protein Degraders and Molecular Glues
Cochairs: Susan M. Galbraith, AstraZeneca, Cambridge, England, and Kevan M. Shokat, University of California, San Francisco, California
2:10 – 4 p.m.

Introduction

Title to be announced
Craig M. Crews, Yale University, New Haven, Connecticut

Title to be announced
Brenda A. Schulman, Max Planck Institute of Biochemistry, Martinsried, Germany

Title to be announced
Benjamin L. Ebert, Dana Farber Cancer Institute, Boston, Massachusetts

Panel Discussion

Break
4 – 4:15 p.m.
Closing Session: What is the Biggest Roadblock in Anticancer Drug Development in the Next Decade and What Can be Done to Mitigate?
Moderator: Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
4:15 – 5:45 p.m.

Panelists:
Emiliano Calvo, START Madrid, Madrid, Spain
Levi A. Garraway, Genentech, South San Francisco, California
James L. Gulley, National Cancer Institute, Bethesda, Maryland
Maria T. Koehler, REPARE Therapeutics, Montreal, QC, Canada
Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, England
Tatiana M. Prowell, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, U.S. Food and Drug Administration, Baltimore, Maryland
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain